MX2018015397A - Co-cristales de benzoato de sodio y sus usos. - Google Patents
Co-cristales de benzoato de sodio y sus usos.Info
- Publication number
- MX2018015397A MX2018015397A MX2018015397A MX2018015397A MX2018015397A MX 2018015397 A MX2018015397 A MX 2018015397A MX 2018015397 A MX2018015397 A MX 2018015397A MX 2018015397 A MX2018015397 A MX 2018015397A MX 2018015397 A MX2018015397 A MX 2018015397A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- sodium benzoate
- compound
- disorders
- hypercholesterolemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/10—Sorbic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
- C07C57/44—Cinnamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349578P | 2016-06-13 | 2016-06-13 | |
| PCT/CN2017/088045 WO2017215593A1 (en) | 2016-06-13 | 2017-06-13 | Co-crystals of sodium benzoate and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015397A true MX2018015397A (es) | 2019-08-16 |
Family
ID=60663996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015397A MX2018015397A (es) | 2016-06-13 | 2017-06-13 | Co-cristales de benzoato de sodio y sus usos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11008277B2 (OSRAM) |
| EP (1) | EP3468944B1 (OSRAM) |
| JP (1) | JP6958922B2 (OSRAM) |
| KR (1) | KR102403048B1 (OSRAM) |
| CN (1) | CN109563018A (OSRAM) |
| CA (1) | CA3027297A1 (OSRAM) |
| DK (1) | DK3468944T3 (OSRAM) |
| ES (1) | ES2936094T3 (OSRAM) |
| FI (1) | FI3468944T3 (OSRAM) |
| IL (1) | IL263492B (OSRAM) |
| MX (1) | MX2018015397A (OSRAM) |
| TW (1) | TWI671287B (OSRAM) |
| WO (1) | WO2017215593A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102488927B1 (ko) | 2016-06-13 | 2023-01-13 | 신유알엑스 인터내셔널 (타이완) 코포레이션 | 벤조산리튬의 공-결정 및 그의 용도 |
| WO2019103597A1 (en) * | 2017-11-22 | 2019-05-31 | Excelsior Pharmatech Labs | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression |
| WO2020176432A1 (en) | 2019-02-25 | 2020-09-03 | Rush University Medical Center | Compositions including cinnamic acid and methods of use thereof |
| US11376277B2 (en) | 2020-06-01 | 2022-07-05 | Celagenex Research (India) Pvt. Ltd. | Synergistic medicinal compositions for treating dysfunctional D-serine signaling |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3498989A (en) | 1969-04-16 | 1970-03-03 | American Home Prod | Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof |
| US3870715A (en) | 1972-03-09 | 1975-03-11 | Nikolaus R Hansl | Substituted amino ethyl meta benzoic acid esters |
| US4041174A (en) | 1974-08-16 | 1977-08-09 | Rom-Amer Pharmaceuticals, Ltd. | Method of treating depression |
| US4731379A (en) * | 1983-12-07 | 1988-03-15 | H.S.C. Corporation | Flea eradicator |
| US5204356A (en) | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| GB8819494D0 (en) | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
| CA2058455A1 (en) * | 1990-12-21 | 1992-06-22 | Mark W. Collison | Synergistic effect of lantibiotics in combination with selected agents against gram positive bacteria |
| CA2104594C (en) * | 1991-02-22 | 2004-05-11 | Howard K. Shapiro | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| FR2700117B1 (fr) | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
| DE4340273A1 (de) | 1993-11-26 | 1995-06-01 | Karla Dr Lehmann | Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung |
| US5441981A (en) * | 1994-01-27 | 1995-08-15 | Buckman Laboratories International, Inc. | Synergistic antimicrobial compositions containing a halogenated acetophenone and an organic acid |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| US6146847A (en) * | 1996-11-01 | 2000-11-14 | Genespan Corporation | Stabilized transient gene expression |
| DE19925425A1 (de) * | 1999-06-02 | 2000-12-07 | Wessollek Heimo | Mittel zur Entkeimung bzw. keimreduzierenden Gestaltung von Reinigungs-, Sanitär- und Toilettenartikeln sowie kosmetischen Artikeln, Körperpflegeartikeln und dergleichen verkeimungsgefährdeten Gegenständen |
| AU4517201A (en) | 1999-12-08 | 2001-06-18 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| WO2002014286A1 (en) | 2000-08-14 | 2002-02-21 | Teva Pharmaceutical Industries Ltd. | Preparation of risperidone |
| US20030185754A1 (en) | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| EA006654B1 (ru) | 2001-01-16 | 2006-02-24 | Женсет С. А. | Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20100311701A1 (en) | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
| US20070053976A1 (en) | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| WO2004037234A2 (en) | 2002-10-24 | 2004-05-06 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| CA2798615A1 (en) * | 2003-01-21 | 2004-08-05 | Aptuit (West Lafayette), Llc | Novel cocrystallization of hydrochloric acid salt of an active agent |
| US7452555B2 (en) | 2003-01-21 | 2008-11-18 | S.S.C.I., Inc. | Cocrystallization |
| WO2004065348A1 (en) | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| JP2006526635A (ja) | 2003-06-02 | 2006-11-24 | サマリタン,ファーマスーティカルス,インク. | 血清中コルチゾール量を調節する方法および組成物 |
| BRPI0417910A (pt) | 2003-12-29 | 2007-04-10 | Sepracor Inc | composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto |
| EP1709053B1 (en) | 2004-01-27 | 2011-04-06 | Synthon B.V. | Stable salts of olanzapine |
| US20050267176A1 (en) | 2004-02-18 | 2005-12-01 | Sepracor Inc. | Dopamine-agonist combination therapy for improving sleep quality |
| CA2565159A1 (en) | 2004-05-06 | 2005-12-15 | Cydex, Inc. | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
| WO2006007448A2 (en) | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
| WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| CA2505808A1 (en) * | 2005-05-02 | 2006-11-02 | Julie Danielle Globus | Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans |
| WO2006129160A2 (en) | 2005-06-01 | 2006-12-07 | Aurobindo Pharma Limited | Stable aqueous oral solution of risperidone |
| US20110045065A1 (en) | 2005-07-11 | 2011-02-24 | Ashok Vasantray Vyas | Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| GB0603181D0 (en) | 2006-02-17 | 2006-03-29 | Merck Sharp & Dohme | Treatment of neurodegenerative and psychiatric diseases |
| US20080045547A1 (en) * | 2006-07-07 | 2008-02-21 | Lippa Arnold S | Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use |
| US20080045512A1 (en) | 2006-08-09 | 2008-02-21 | Pfizer Inc. | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane |
| WO2008034087A2 (en) | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Treating schizophrenia with combinations of levodopa and an antipsychotic agent |
| EP2167043A4 (en) * | 2007-06-06 | 2013-05-01 | Univ South Florida | NEW USE CO-CRYSTAL COMPOSITIONS |
| US8071143B2 (en) * | 2008-04-02 | 2011-12-06 | Brandeis University | Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances |
| US20130338199A1 (en) | 2008-07-11 | 2013-12-19 | Uday Saxena | Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease |
| GB0813709D0 (en) | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
| WO2010027921A1 (en) * | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
| JP2010106001A (ja) * | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ppar活性化剤 |
| EP3006024B1 (en) * | 2009-01-20 | 2019-03-20 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Benzoic acid or salts thereof to enhance the activity of a neuropharmaceutical |
| DK3656765T3 (da) | 2010-07-23 | 2021-06-14 | Gruenenthal Gmbh | Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol |
| JP2014508814A (ja) | 2011-03-24 | 2014-04-10 | ユニバーシティ・オブ・サウス・フロリダ | リチウム組成物 |
| TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
| PH12012000132B1 (en) * | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
| US9120766B2 (en) * | 2011-10-21 | 2015-09-01 | Amri Ssci, Llc | Methods of making cocrystals |
| JP6205406B2 (ja) * | 2012-03-30 | 2017-09-27 | ナフォーミックス リミテッド | トラニラスト組成物および共結晶 |
| ES2910003T3 (es) * | 2013-04-19 | 2022-05-11 | Univ South Florida | Compuestos y composiciones de cocristal iónico de litio de anión orgánico |
| WO2014178040A1 (en) | 2013-04-29 | 2014-11-06 | Mapi Pharma Ltd. | Co-crystals of dapagliflozin |
| KR102411227B1 (ko) * | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| ES2788866T3 (es) * | 2013-12-13 | 2020-10-23 | Conaris Res Institute Ag | Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida para su uso en influir beneficiosamente en los niveles de lípidos en sangre mediante la modificación de la microbiota intestinal |
| SG11201507188QA (en) * | 2014-03-24 | 2015-10-29 | Kaohsiung Chang Gung Memorial Hospital | Use of benzoic acid salt in the manufacture of a composition for preventing or treating dementia or mild cognitive impairment |
| CN103992320A (zh) * | 2014-05-26 | 2014-08-20 | 南京工业大学 | 一种混悬结晶制备药物共晶的方法 |
| PL3871515T3 (pl) * | 2014-05-27 | 2025-06-16 | R. J. Reynolds Tobacco Company | Sole nikotyny, ko-kryształy i kompleksy ko-kryształów soli |
| US9896429B2 (en) * | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| WO2016081365A1 (en) * | 2014-11-19 | 2016-05-26 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| RU2582962C1 (ru) | 2014-12-23 | 2016-04-27 | Ольга Алексеевна Громова | Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты) |
| KR102488927B1 (ko) * | 2016-06-13 | 2023-01-13 | 신유알엑스 인터내셔널 (타이완) 코포레이션 | 벤조산리튬의 공-결정 및 그의 용도 |
| JP2019522067A (ja) | 2016-06-14 | 2019-08-08 | エマージ リミテッド ライアビリティ カンパニー | 炭化器高温ガスの炭化水素再生利用 |
| US10064833B2 (en) * | 2016-08-04 | 2018-09-04 | Syneurx International (Taiwan) Corp. | Compositions containing benzoate compound and tannic acid for treating central nervous system disorders |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US9877942B1 (en) * | 2017-02-13 | 2018-01-30 | Syneurx International (Taiwan) Corp. | Co-crystals of substituted glycine and uses thereof |
| US20190076472A1 (en) * | 2017-09-14 | 2019-03-14 | CT Development One, LLC | Hyperammonemia therapy for children suffering from urea cycle disorders |
| US10098861B1 (en) * | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
-
2017
- 2017-06-13 TW TW106119576A patent/TWI671287B/zh active
- 2017-06-13 JP JP2018564884A patent/JP6958922B2/ja active Active
- 2017-06-13 ES ES17812704T patent/ES2936094T3/es active Active
- 2017-06-13 FI FIEP17812704.9T patent/FI3468944T3/fi active
- 2017-06-13 US US16/309,349 patent/US11008277B2/en active Active
- 2017-06-13 WO PCT/CN2017/088045 patent/WO2017215593A1/en not_active Ceased
- 2017-06-13 MX MX2018015397A patent/MX2018015397A/es unknown
- 2017-06-13 CN CN201780047165.6A patent/CN109563018A/zh active Pending
- 2017-06-13 DK DK17812704.9T patent/DK3468944T3/da active
- 2017-06-13 CA CA3027297A patent/CA3027297A1/en active Pending
- 2017-06-13 EP EP17812704.9A patent/EP3468944B1/en active Active
- 2017-06-13 KR KR1020197000864A patent/KR102403048B1/ko active Active
-
2018
- 2018-12-04 IL IL263492A patent/IL263492B/en unknown
-
2021
- 2021-05-03 US US17/306,005 patent/US11731928B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201802065A (zh) | 2018-01-16 |
| US11008277B2 (en) | 2021-05-18 |
| IL263492A (en) | 2019-01-31 |
| WO2017215593A1 (en) | 2017-12-21 |
| KR20190018477A (ko) | 2019-02-22 |
| RU2019100436A (ru) | 2020-07-14 |
| IL263492B (en) | 2021-08-31 |
| JP2019518756A (ja) | 2019-07-04 |
| EP3468944B1 (en) | 2022-11-16 |
| US20210340094A1 (en) | 2021-11-04 |
| US11731928B2 (en) | 2023-08-22 |
| CA3027297A1 (en) | 2017-12-21 |
| FI3468944T3 (fi) | 2023-01-31 |
| US20190169110A1 (en) | 2019-06-06 |
| EP3468944A4 (en) | 2020-02-12 |
| EP3468944A1 (en) | 2019-04-17 |
| DK3468944T3 (da) | 2023-02-06 |
| CN109563018A (zh) | 2019-04-02 |
| KR102403048B1 (ko) | 2022-05-26 |
| RU2019100436A3 (OSRAM) | 2020-07-14 |
| TWI671287B (zh) | 2019-09-11 |
| ES2936094T3 (es) | 2023-03-14 |
| JP6958922B2 (ja) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| AR110747A1 (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| HK1220325A1 (zh) | 苯并咪唑衍生物及其用途 | |
| MX2018015397A (es) | Co-cristales de benzoato de sodio y sus usos. | |
| GEP20196949B (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| MX377304B (es) | Derivados de piperazina como moduladores de los receptores x del hígado. | |
| IL278813A (en) | Gene therapy for Alzheimer's disease | |
| CY1114877T1 (el) | Παραγωγα φαινυλ πυραζολιου | |
| ZA202205344B (en) | Gene therapy for alzheimer's disease | |
| IL288266A (en) | Gene therapy for Alzheimer's disease | |
| NZ707946A (en) | Hydantoin derivative | |
| PH12015502676A1 (en) | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator | |
| MX2016000724A (es) | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| MX2016014118A (es) | Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes. | |
| MX2017013694A (es) | Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son utiles en el tratamiento de la enfermedad de alzheimer. | |
| IN2013MU01124A (OSRAM) | ||
| MX2018015463A (es) | Co-cristales de benzoato de litio y sus usos. | |
| EA201791398A1 (ru) | Производные фумагиллола | |
| ZA202006126B (en) | Compounds for treating alzheimer's disease | |
| EP4324523A3 (en) | New methods for the treatment of multiple sclerosis | |
| EA201692485A1 (ru) | Новая полиморфная форма n-[2-(6-фтор-1h-индол-3-ил)этил]-3-(2,2,3,3-тетрафторпропокси)бензиламина гидрохлорида для лечения болезни альцгеймера | |
| EA201792076A1 (ru) | Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний |